Table 3 Clinical trials where the safety and efficacy of nanomaterials were evaluated for use in lung cancer immunotherapy
From: Lung cancer immunotherapy: progress, pitfalls, and promises
Clinical Trial ID | Drug | Delivery System | Cancer | Status | Duration | Sponsor/ Agency |
|---|---|---|---|---|---|---|
NCT 02,049,151 | Tecemotide Following Concurrent Chemo-radiotherapy | Liposome | Unresectable Stage III NSCLC | Phase III (USA) | 2014–2015 | EMD Serono/Oncothyreon Canada Inc |
NCT 00,960,115 | Tecemotide Following Chemotherapy | Liposome | Unresectable Stage III NSCLC | phase I/II (Japan) | 2009–2015 | Merck KGaA, Darmstadt, Germany |
NCT 01,015,443 | Tecemotide Following primary Chemo-radiotherapy | Liposome | Unresectable Stage III NSCLC | Phase III (Asian population) | 2009–2015 | Merck KGaA, Darmstadt, Germany |
NCT 00,828,009 | Tecemotide with bevacizumab after chemotherapy and radiation therapy | Liposome | Unresectable Stage IIIA/IIIB NSCLC | Phase II (USA) | 2010–2019 | ECOG-ACRIN Cancer Research Group |
NCT 00,157,196 | Tecemotide with single-dose low CPA | Liposome | Stage IIIA NSCLC | Phase II | 2005–2012 | Merck KGaA, Darmstadt, Germany |
NCT 00,157,209 | Tecemotide with single-dose low CPA | Liposome | Stage IIIB/Stage IV NSCLC | Phase IIB (Germany) | 2000–2012 | Merck KGaA, Darmstadt, Germany |
NCT 00,409,188 | Tecemotide with single-dose low CPA | Liposome | Unresectable Stage III NSCLC | Phase III (23 countries) | 2007–2012 | EMD Serono |
NCT 03,836,352 | DPX-Survivac with low dose Cyclophosphamide & Pembrolizumab | Liposome | NSCLC and other carcinomas | Phase II (USA/Canada) | 2018–2023 | ImmunoVaccine Technologies, Inc. (IMV Inc.) |
NCT 00,291,473 | Mixed cancer vaccines, CHP-HER2 and CHP-NY-ESO-1 with OK-432 (Picibanil) | Cholesterol-Bearing Hydrophobized Pullulan | Lung cancer and other carcinomas | Phase I (Japan) | 2005–2008 | Ludwig Institute for Cancer Research |
NCT 01,853,878 | Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A | Liposome | NSCLC after removal of the tumor | Phase II (9 countries) | 2013–2016 | GlaxoSmithKline |
NCT 01,258,868 | Tumor Cell Vaccines with ISCOMATRIX Adjuvant and Celecoxib | Liposome | Lung cancer and other carcinomas | Phase I (USA) | 2010–2016 | National Cancer Institute (NCI) |